Myo inositol PCOS: studies, doses, side effects, and legal status

Myo-inositol for fertility is one of the topics you quickly run into if you have PCOS: in forums, in trying-to-conceive groups, and on the product pages of powders and capsules. The hope behind it is understandable. A powder in a glass of water seems simpler than an appointment at a fertility clinic.

The evidence is more sobering. The international PCOS guideline classifies inositol in any form as an experimental therapy for women with PCOS who want to conceive: Benefits and risks are too uncertain to recommend it as a fertility treatment (Teede 2023, recommendation 5.8.1). The DACH guideline before fertility treatment (the joint guideline for Germany, Austria, and Switzerland) considers the data insufficient for a recommendation (AWMF 015-085, 2026). And the British NICE draft from July 2026 wants to tell affected people that inositol is not effective for fertility problems (NICE 2026, draft).

Here you will read what lies behind these assessments: which studies exist, how more positive reviews should be interpreted, which doses were given in studies, what is known about side effects, and what an inositol product may legally promise. We deliberately do not give our own dosage recommendation or product recommendation.

What is myo-inositol?

Inositol comes in several forms. The studies on PCOS involve two of them: myo-inositol (MI) and D-chiro-inositol (DCI). Both occur in the body. For the ovary, the guideline meta-analysis gives a ratio of MI to DCI of about 100 to 1 without PCOS and 0.2 to 1 with PCOS (Fitz 2024). From such differences, it is inferred that a particular mixing ratio could make sense. Whether that is true is an open question; there is more on this in the section on D-chiro-inositol.

The studies measured, for example, insulin resistance (via the HOMA-IR value), the cycle, ovulation, and the pregnancy rate.

Legally, inositol is not a nutrient like vitamins and minerals but an “other substance” (Section 1(2) of the German Dietary Supplement Ordinance, NemV). It is sold as a dietary supplement. No approval is needed for that, and there is no legal maximum amount. What this means for advertising claims is explained under Legal status.

PCOS is now called PMOS: Since May 2026, polycystic ovary syndrome has been internationally called Polyendocrine Metabolic Ovarian Syndrome, or PMOS for short. About one in eight women is affected, more than 170 million worldwide. A total of 56 patient and professional organizations were involved (Endocrine Society 2026). A three-year transition period applies, and the name will be fully implemented with the update of the international guideline in 2028. Until then, the 2023 guideline remains authoritative. There is no uniform German name yet; the DACH guideline uses “Polymetabolisches Ovarialsyndrom” (polymetabolic ovarian syndrome; AWMF 015-085, 2026). We stick with PCOS because most people search for it.

What the guidelines say about inositol when you are trying to conceive

None of the guidelines and position statements we examined recommends inositol as a fertility treatment. They differ mainly in how clearly they say so.

NICE is the most explicit. The committee considers the wording of the international guideline not directive enough and wants to make clear, in plain language, that inositol in PCOS is not effective for fertility questions (NICE adaptation report 2026). This is still a draft: The consultation ran from July 1 to August 11, 2026, and the final guideline is announced for January 27, 2027. Until then, the wording may change.

For adolescents with PCOS, the international adolescent recommendations do not recommend inositol: There are no data for this group, and in adults only an effect on laboratory values has been shown (Peña 2025).

What the studies show when you are trying to conceive

Myo-inositol before IVF or ICSI: the Cochrane review

The Cochrane review of inositol in women with PCOS and infertility includes 13 randomized trials with 1,472 women. In 11 trials, the women received myo-inositol as pretreatment before IVF or ICSI, in 2 trials during ovulation induction (Showell 2018, search date July 2018). We did not find a more recent version.

How to read the numbers: An odds ratio (OR) or a relative risk (RR) above 1 means the event was more common with inositol, below 1 less common. If the 95% confidence interval (CI) includes 1, a difference is not established.

The miscarriage rate initially looked lower with myo-inositol. But the result rests mainly on one trial in which the comparison group had an unusually high number of miscarriages. Without this trial, the effect disappeared (Cochrane 2018).

Data box: What “between 9 and 51%” means

Cochrane converts the live birth result into absolute numbers. If 12 of 100 women who take only folic acid before IVF (standard treatment) have a baby, then with myo-inositol it would be anywhere between 9 and 51 of 100. So the range extends from somewhat fewer to considerably more births. The reason is the small data basis of 84 women in 2 trials. No benefit can be inferred from this, and no harm either.

The guideline meta-analysis with an integrity check

For the international guideline, a team led by Fitz collected randomized trials on inositol in PCOS and additionally checked them for trustworthiness (Fitz 2024). Of 43 trials, 13 with a moderate risk of integrity problems were excluded, and 30 trials with 2,230 participants were included. The conclusion: The evidence for inositol in PCOS is limited and not conclusive. Any decision should be made together, with this uncertainty in mind.

Compared with inositol, metformin possibly improved the waist-to-hip ratio and excess hair growth more. For fertility, there is probably no difference between the two (Fitz 2024).

Reviews with more positive results

There are also review papers with clearly better numbers. Knowing about them helps you make sense of product texts that cite “meta-analyses.”

Greff 2023: The German PCOS guideline cites a meta-analysis of 26 trials with 1,691 patients in which normal periods (eumenorrhea) were more common with inositol than with placebo (RR 1.79). The guideline itself regards the conclusions that can be drawn from this meta-analysis as markedly limited, because many small trials with different designs were included (AWMF 089-004). According to Fitz, this analysis partly contained trials that were excluded in the integrity check for the international guideline.

Umbrella review 2026: A review from February 2026 summarizes 13 meta-analyses; the literature search ran until August 2025. Compared with placebo or folic acid, it reports more live births (RR 2.29; 95% CI 1.07 to 4.93), a higher ovulation rate (RR 2.75), and a HOMA-IR value that was lower by 1.14 on average. Compared with metformin, most differences were not significant; exceptions were triglycerides and pregnancy rate, both in favor of inositol. Of 85 outcomes assessed, none reached a high certainty of evidence: 18.9% moderate, 40% low, 41.1% very low.

Important context: The umbrella review does not mention an integrity check. The integrity-checked guideline meta-analysis by Fitz is not included, but the analysis by Greff is.

Network meta-analysis on IVF 2024: This work compares drugs before IVF or ICSI in PCOS in 20 trials with 1,827 patients. Of these, only 150 received myo-inositol; most received metformin (818), and others pioglitazone, simvastatin, or sitagliptin. No agent significantly improved pregnancy outcomes. With myo-inositol and with metformin, the risk of ovarian hyperstimulation syndrome (OHSS) was lower. With myo-inositol, the hormone injections (gonadotropins) were given for a shorter time, and side effects were less common than in the control groups (OR 0.23; 95% CI 0.06 to 0.83). The statements on myo-inositol therefore rest on a small subgroup.

Taken together: The analysis by Greff and the umbrella review partly include trials that the guideline analysis sorted out because of integrity doubts. The network meta-analysis found no benefit for pregnancy but rests on only 150 women for myo-inositol. The integrity-checked guideline analysis finds no established benefit when trying to conceive.

Inositol in PCOS without trying to conceive: metabolism and cycle

Outside the context of trying to conceive, the international guideline sees inositol as a possible option depending on personal preferences: little harm, possible improvements in metabolic values, but limited clinical benefit for ovulation, excess hair growth (hirsutism), and weight (Teede 2023, recommendation 4.7.1, conditional, very low certainty of evidence). For hirsutism and abdominal fat (central obesity), metformin should be preferred, though it causes more gastrointestinal side effects (4.7.2).

The guideline cannot recommend a particular form, dose, or combination because of the lack of high-quality evidence, for adults or for adolescents. This also applies to mixtures of MI and DCI in fixed ratios (practice point 4.7.4).

The Canadian professional society SOGC is somewhat more positive. It considers inositol in PCOS in general an option, with low potential for harm and possible improvements in metabolism and cycle (recommendation 3, conditional, low evidence). According to the SOGC, myo-inositol can be used as an alternative to metformin for cycle and ovulation, depending on preferences and side effects (recommendation 4, weak, moderate evidence).

The NICE draft advises restraint here as well: People aged 18 and over who are affected should be told that the clinical benefit of inositol for metabolic problems is uncertain (recommendation 1.12.3, draft 2026).

What else myo-inositol has been studied for

Gestational diabetes

During pregnancy, myo-inositol has been studied for preventing gestational diabetes. A Cochrane review summarizes 7 trials with 1,319 pregnant women, 6 from Italy and 1 from Ireland. Supplementation started between week 10 and week 24 of pregnancy.

In the inositol groups, gestational diabetes occurred less often (RR 0.53; 95% CI 0.31 to 0.90; 6 trials, 1,140 women), as did hypertensive disorders in pregnancy (RR 0.34; 95% CI 0.19 to 0.61; 5 trials, 1,052 women). The certainty of evidence is low to very low (Cochrane 2023).

Two limits matter for women who are trying to conceive. The data say nothing about taking it before conception and in early pregnancy before week 10. And women with pre-existing type 1 or type 2 diabetes were excluded. There is no approved claim that inositol lowers the risk of gestational diabetes (Health Claims Regulation, HCVO, Art. 14).

D-chiro-inositol and the 40:1 ratio

One mixing ratio is mentioned especially often: 40 parts myo-inositol to 1 part D-chiro-inositol. According to the research group led by Nordio, this corresponds to the natural ratio in blood plasma. The guideline meta-analysis reports the classification as “physiological” only as a suggestion. The evidence cited consists of mouse models and one small, open-label human study (Fitz 2024).

This often-cited study (Nordio 2019) treated 56 women with PCOS, 8 per group, with DCI alone or one of six MI/DCI ratios. They received 2 g of inositol twice daily for 3 months. The main outcome was ovulation; the authors consider 40:1 the best ratio for restoring it.

The guideline meta-analysis found only 2 small trials that directly compared mixing ratios: the Nordio study (55 women in the analysis, 7 groups, 4 g per day in total) and a study of 34 women that compared 3.6:1 with 40:1, each over 3 months. For insulin resistance (HOMA-IR), the most important endpoint of the guideline analysis, neither found a difference, and that includes the Nordio study (Fitz 2024). The 40:1 ratio therefore rests on animal data and this very small human study. Robust confirmation in humans is lacking.

The 40:1 preparation from the manufacturer Lo.Li. Pharma that was used in studies contains 1,100 mg of myo-inositol and 27.6 mg of D-chiro-inositol per day, divided into 2 capsules. That is considerably less myo-inositol than the 4 g per day in the pure MI studies. The comparison of this combination with 4 g of myo-inositol had a very low certainty of evidence (Fitz 2024).

D-chiro-inositol alone was tested against placebo in only 2 small studies with 20 and 44 participants, 32 women per group when pooled, with 600 to 1,200 mg of DCI per day. The ovulation rate was higher with DCI (OR 11.50; 95% CI 3.40 to 38.91); the certainty of evidence is low because of very serious imprecision. In both studies, ovulation was defined as a blood progesterone level above 8 ng/ml. For BMI, placebo did better than DCI (mean difference 0.67; Fitz 2024).

High DCI doses might be unfavorable: In one study, 54 women with PCOS received placebo or 300 to 2,400 mg of DCI daily for 8 weeks before IVF stimulation. With the higher doses, the FSH requirement and the share of immature eggs rose, and the number of good embryos fell (Isabella 2012). Women with insulin resistance or elevated blood sugar were excluded, so the results apply only to women without insulin resistance. Since 2018, the paper has carried an “Expression of Concern” from the journal and is therefore usable only to a limited extent.

Myo-inositol dosage: what was given in studies

There is no recommended dose. According to the international guideline, no particular form, dose, or combination can be recommended because of the lack of high-quality evidence (practice point 4.7.4). The table therefore shows only what was given in studies. It is not a recommendation for you.

The amounts differ widely, depending on form and combination. What amount would make sense cannot be derived from this; the guideline sees insufficient evidence for it.

For dietary supplements, the following applies: The package shows a recommended daily intake, together with the mandatory notice that it must not be exceeded (Section 4(2) of the Dietary Supplement Ordinance). Study doses are information about studies. They are not a recommendation to take more than what is on the package. If you want to take inositol, discuss the product and amount with your gynecologist or your fertility clinic.

Side effects and safety

There are fewer data on safety than the many studies might suggest. The international guideline states: Side effects and safety of inositol are not known (practice point 5.8.3). Products can be poorly regulated, with varying dose, quality, and consistency and with admixtures of other substances (5.8.4).

• Barely recorded: In the guideline meta-analysis, 23 of 29 trials gave no information on adverse events (Fitz 2024).
• Gastrointestinal complaints: A safety review found mild complaints such as nausea, bloating, and diarrhea only at the highest dose studied, 12 g of myo-inositol per day. Their severity did not increase with the dose (Carlomagno 2011). On the conflict of interest: Author G. Carlomagno is listed with the research department of the inositol manufacturer Lo.Li. Pharma in a 2015 consensus publication (Facchinetti 2015).
• Compared with metformin: Gastrointestinal side effects occurred clearly less often with myo-inositol (OR 0.09; moderate certainty of evidence; Fitz 2024).
• Short term and long term: In the short term, inositol is considered well tolerated, with few reported side effects. Data on long-term safety from clinical trials are lacking (SOGC 2025).
• Before and in early pregnancy: We did not find systematic safety data for the time before conception and before week 10 of pregnancy. The gestational diabetes trials started no earlier than week 10 (Cochrane 2023).
• High D-chiro doses: Indications of unfavorable effects before IVF come from a study under an “Expression of Concern,” see D-chiro-inositol.

Combining myo-inositol with metformin or folic acid?

With metformin

Metformin is a medication, inositol a dietary supplement. The guideline meta-analysis lists two trials in which both were combined (Fitz 2024):

• 50 women: 1 g myo-inositol plus 1 g metformin versus 1 g metformin daily over 4 months. There was no difference in BMI, weight, and fasting insulin.
• 72 women: 1.1 g myo-inositol plus 0.3 g D-chiro-inositol plus 1 g metformin versus metformin alone over 6 months. The combination did better on cycle irregularities (38.9% versus 63.9%, P = 0.034), total cholesterol, HDL, LDL, and insulin after eating. There was no difference in hair growth, male hormones, body measurements, and blood sugar. The certainty of evidence is low.

Interactions between inositol and metformin are not described in the guidelines and review papers this article is based on. However, we did not find a prescribing information document or an interaction database that confirms this. If you take metformin and would like to add inositol, discuss this with your doctor beforehand.

With folic acid

In many fertility studies, myo-inositol was given together with folic acid and compared with folic acid alone. In the Cochrane review, folic acid alone counts as the standard treatment of the comparison group. These studies therefore test whether inositol makes a difference in addition to folic acid: In the guideline meta-analysis, there was no significant difference in clinical pregnancy (OR 1.24; Fitz 2024).

Folic acid itself is a topic of its own. There is an approved health claim for it on neural tube defects, but products may use it only if they contain at least 400 µg of folic acid per daily portion. In combination products, this claim may refer only to the folic acid, never to the inositol (Health Claims Regulation). How much folic acid is recommended when trying to conceive, and from when, is covered in the article Folic acid for fertility. Which other vitamins are discussed is explained in the overview Fertility vitamins. What common fertility supplements contain in terms of folic acid, iodine, vitamin D, and DHA, measured against the official recommendations, is shown in our supplement comparison.

Legal status: dietary supplements without an approved health claim

This section applies to Germany, Austria, and Switzerland.

In Germany and Austria, EU law applies directly to inositol products. Switzerland has its own food law, which likewise prohibits therapeutic claims and maintains its own list of permitted health-related claims. The notes on the Dietary Supplement Ordinance (NemV), the Federal Office of Consumer Protection and Food Safety (BVL), the Therapeutic Products Advertising Act (HWG), and the Medicinal Products Act (AMG) refer to Germany.

No health claim has been authorized in the EU for inositol itself. Two claims were applied for and rejected: “Important for the function of the nervous system,” because the effect was not sufficiently defined, and “Contributes to mental performance/concentration,” because the effect was not substantiated. The only authorized claim in which an inositol compound appears at all concerns lowering LDL cholesterol through a fixed combination that contains, among other things, 500 mg of red yeast rice and 9 mg of inositol hexanicotinate per day. It has nothing to do with inositol as a single substance or with fertility (EU register).

A notification to the German Federal Office of Consumer Protection and Food Safety (BVL) is not an examination. “Checked by the BVL” or “officially approved” therefore does not apply to an inositol product (Section 5 of the Dietary Supplement Ordinance). Myo-inositol is not considered a novel food in the EU. D-chiro-inositol from non-novel plant sources is considered non-novel only in dietary supplements (EU Novel Food Catalogue).

If an inositol product is presented as a means of treating PCOS or infertility, it can be considered a medicinal product that is not approved (Section 2(1) No. 1 of the Medicinal Products Act, AMG). An exception is foods for special medical purposes: Only for them is a reference to disease permitted, within narrow limits and under medical supervision (Regulation (EU) No. 609/2013).

For you, this means: If an inositol product promises more fertility, better ovulation, or help with PCOS, that is not a tested and approved statement.

Myo-inositol reviews and experiences: what personal reports can show

If you search for experiences with myo-inositol, you will find reports in forums and on social media from women who became pregnant after taking it and from others for whom nothing changed.

Such reports cannot show whether a pregnancy occurred because of inositol or would have happened without it. That is exactly what randomized trials with a comparison group are for. In them, a benefit when trying to conceive is not established (Cochrane 2018, Fitz 2024).

That is why you will find no personal accounts here, but the studies themselves.

When medical treatment matters more

None of the guidelines examined recommends inositol as a fertility treatment. The German PCOS guideline sees no higher ovulation, pregnancy, or live birth rate with myo-inositol alone (AWMF 089-004). If you want to get pregnant with PCOS, the question of treatment therefore belongs in a conversation with a doctor.

Which treatments the guidelines provide for PCOS, from letrozole to metformin to IVF, and what they achieve in studies is explained in our article Getting pregnant with PCOS. When an evaluation makes sense and what causes exist in women and men is covered in the infertility guide. What LH urine tests show in PCOS and where their limits lie, you can read in the article on the ovulation test.

If you want to take inositol anyway:

• Talk it over: with your gynecologist or your fertility clinic, especially if you take metformin or other medications.
• Not instead of treatment: No guideline provides for inositol as a replacement for medical treatment.
• Package, not study: Stick to the intake amount on the package. Study doses are not a recommendation.
• Keep pregnancy in mind: For the time before conception and the first weeks of pregnancy, systematic safety data are lacking.

You can find clinics near you in the clinic directory, and guidance for your next step in the Fertility Clinic Finder.

Frequently asked questions

Can inositol help you get pregnant?

A benefit is not established. The international PCOS guideline classifies inositol as experimental when trying to conceive, the German PCOS guideline sees no higher ovulation, pregnancy, or live birth rate with myo-inositol alone, and the NICE draft says inositol is not effective for fertility problems (Teede 2023, AWMF 089-004, NICE 2026).

How much myo-inositol per day when trying to conceive?

There is no recommended dose: Because of the lack of high-quality evidence, the international guideline cannot recommend any form, dose, or combination (Teede 2023). In 6 of 8 trials of myo-inositol plus folic acid, it was 4 g of myo-inositol with 200 to 400 µg of folic acid daily, in 2 trials 2 g, each over 4 to 12 weeks (Fitz 2024). These are study figures, not a recommendation to take more than what is on the package.

What is the difference between myo-inositol and D-chiro-inositol?

Both are forms of inositol that occur in the body. For the ovary, the guideline meta-analysis gives a ratio of MI to DCI of about 100 to 1 without PCOS and 0.2 to 1 with PCOS (Fitz 2024). That a mixture in a 40:1 ratio is better than others has not been robustly shown in humans. High D-chiro doses were associated with less favorable results before IVF in one study, but this study is usable only to a limited extent (Isabella 2012).

Can I take myo-inositol together with metformin?

In two trials, both were combined, and interactions are not described in the guidelines and reviews examined. A reliable interaction source is lacking, however. In direct comparison, there was no difference between myo-inositol and metformin in the pregnancy rate; gastrointestinal complaints were less common with myo-inositol (Fitz 2024). Discuss the combination with your doctor.

Does myo-inositol have side effects?

In the short term, it is considered well tolerated (SOGC 2025). In a safety review, mild gastrointestinal complaints occurred only at 12 g per day; one author is listed in 2015 with the research department of an inositol manufacturer (Carlomagno 2011, Facchinetti 2015). According to the international guideline, however, side effects and safety are not known, and most studies did not record them at all (Teede 2023, Fitz 2024).

Can I keep taking myo-inositol during pregnancy?

It is best to discuss this with your gynecologist. The gestational diabetes trials started no earlier than week 10 of pregnancy and provide no data for the time before that or before conception (Cochrane 2023). The international guideline calls the safety of inositol unknown (Teede 2023).

What do myo-inositol reviews and experiences tell you?

Individual reports cannot show whether a pregnancy came about through inositol or would have happened without it. That takes trials with a comparison group, and in these a benefit when trying to conceive is not established (Cochrane 2018, Fitz 2024).

Does myo-inositol help before IVF or ICSI?

That is uncertain. Whether myo-inositol raises the live birth rate before IVF could not be clarified in 2 trials with 84 women (OR 2.42; 95% CI 0.75 to 7.83); for clinical pregnancy, no benefit was shown (Cochrane 2018). A network meta-analysis found significantly better pregnancy outcomes for none of the agents examined, but only 150 women there received myo-inositol (network meta-analysis 2024).

Sources

Guidelines and position statements

• Teede HJ et al.: Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, J Clin Endocrinol Metab 2023;108(10):2447-2469, International PCOS Network, 2023
• S2k guideline: Diagnosis and treatment of polycystic ovary syndrome (PCOS), AWMF 089-004, version 1.1, DGE and BDI, 2025
• S2k guideline: Diagnosis and treatment before medically assisted reproduction treatment, AWMF 015-085, version 2.0, DGGG, OEGGG, and SGGG, as of April 2026
• Polyendocrine metabolic ovarian syndrome (previously known as polycystic ovary syndrome): assessment and management, Draft guideline GID-NG10436, NICE, July 2026
• Polycystic ovary syndrome: adaptation report for assessment and treatment of infertility, Adaptation report 5, NICE, July 2026
• Polyendocrine Metabolic Ovarian Syndrome (PMOS), In development GID-NG10436, NICE, 2026
• SOGC Position Statement: Inositol for the Management of Polycystic Ovary Syndrome, Society of Obstetricians and Gynaecologists of Canada, February 2025
• Peña AS et al.: International evidence-based recommendations for polycystic ovary syndrome in adolescents, BMC Med 2025
• ESHRE Add-ons working group: Good practice recommendations on add-ons in reproductive medicine, Hum Reprod 2023;38(11):2062-2104, ESHRE, 2023
• Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide, press release, Endocrine Society, May 12, 2026

Cochrane reviews and meta-analyses

• Showell MG et al.: Inositol for subfertile women with polycystic ovary syndrome, Cochrane Database Syst Rev 2018, CD012378.pub2, Cochrane, 2018
• Motuhifonua SK et al.: Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes, Cochrane Database Syst Rev, Cochrane, 2023
• Fitz V et al.: Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines, J Clin Endocrinol Metab 2024;109(6):1630-1655
• Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome, J Ovarian Res 2024;17:249
• Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials, Front Endocrinol 2026;17:1741509

Studies

• Nordio M et al.: The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios, Eur Rev Med Pharmacol Sci 2019;23(12):5512-5521
• Isabella R, Raffone E: Does ovary need D-chiro-inositol?, J Ovarian Res 2012;5(1):14, Expression of Concern 2018
• Carlomagno G, Unfer V: Inositol safety: clinical evidences, Eur Rev Med Pharmacol Sci 2011;15(8):931-936
• Facchinetti F et al.: Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology, Eur J Obstet Gynecol Reprod Biol 2015;195:72-76

Law

• EU Register on nutrition and health claims, entries POL-HC-7285, POL-HC-7286, and POL-HC-8525, European Commission
• EU Novel Food Catalogue, entry Inositol (POL-NF-13885), European Commission, 2025
• Dietary Supplement Ordinance (NemV), Federal Ministry of Justice
• Act on Advertising in the Field of Healthcare (Therapeutic Products Advertising Act, HWG), Federal Ministry of Justice
• Regulation (EC) No. 1924/2006 on nutrition and health claims made on foods (HCVO), Official Journal of the EU, 2006
• Regulation (EU) No. 1169/2011 on the provision of food information to consumers (LMIV), Official Journal of the EU, 2011